echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Merck's Keytruda combination therapy receives accelerated FDA approval

    Merck's Keytruda combination therapy receives accelerated FDA approval

    • Last Update: 2021-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Merck (MSD) announced today that the US FDA has accelerated the approval of its anti-PD-1 therapy Keytruda in combination with trastuzumab and fluoropyrimidine and platinum-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2 Patients with positive gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma.


    Stomach cancer is the fifth most common cancer in the world and the third leading cause of cancer death.


    Keytruda is a blockbuster anti-PD-1 therapy developed by Merck.


    This accelerated approval is supported by the ongoing randomized, double-blind, placebo-controlled clinical trial KEYNOTE-811.


    In terms of safety, 6% of the patients in the Keytruda combination therapy group and the control group discontinued their participation in the trial due to adverse reactions.


    In the Keytruda group and the placebo group, diarrhea (53% vs.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.